Ertapenem susceptibility of extended spectrum β-lactamase-producing Enterobacteriaceae at a tertiary care centre in India

Singapore Medical Journal

Volumn 50, Issue 6, 2009, Pages 628-632

  Behera, B ^a   Mathur, Purva ^a   Das, A ^a   Kapil, A ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Jai Prakash Narayan Apex Trauma Centre

Author keywords

Enterobacteriaceae; Ertapenem; Extended spectrum lactamase; Multidrug resistant organisms

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CLAVULANIC ACID; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CLINICAL LABORATORY; CONTROLLED STUDY; DISK DIFFUSION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EXPERT SYSTEM; GRAM NEGATIVE BACTERIUM; HUMAN; IN VITRO STUDY; INDIA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HOSPITALS; HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS;

EID: 67849128264     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum beta lactamase producing gram negative bacteria in a tertiary care hospital. Indian J Med Res 2002; 115:153-157 (Pubitemid 35021348)
2. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52:331-344
3. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests, 16th informational supplement. Wayne: National Committee for Clinical Laboratory Standards, 2006. CLSI document no. M2-A9.
4. Barry J, Brown A, Ensor V, et al. Comparative evaluation of the VITEK 2 Advanced Expert System (AES) in five UK hospitals. J Antimicrob Chemother 2003; 51:1191-1202 (Pubitemid 36636893)
5. Cormican MG, Marshall SA, Jones RN. Detection of extendedspectrum beta-lactamase (ESBL)-producing strains by the Etest ESBL screen. J Clin Microbiol 1996; 34:1880-1884.
6. AB BIODISK. ETest ertapenem package insert. Solna, Sweden: AB BIODISK, 2006.
7. Yong D, Lee K, Yum JH, et al. Imipenem-EDTA disk method for differentiation of metallo-beta-lactamase-producing clinical isolates of Pseudomonas spp and Acinetobcter spp. J Clin Microbiol 2002; 40:3798-3801
8. Gupta E, Mohanty S, Sood S, et al. Emerging resistance to carbapenems in a tertiary care hospital in north India. Indian J Med Res 2006; 124:95-98 (Pubitemid 44304650)
9. Mody RM, Erwin DP, Summers AM et al. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms. Ann Clin Microbiol Antimicrob 2007; 6:6.
10. Betriu C, Salso S, Sánchez A, et al. Comparative in vitro activity and the inoculum effect of ertapenem against Enterobacteriaceae resistant to extended-spectrum cephalosporins. Int J Antimicrob Agents 2006; 28:1-5. (Pubitemid 43914398)
11. Livermore D, Oakton K, Carter M, Warner M. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent betalactamases. Antimicrob Agents Chemother 2001; 45:2831-2837 (Pubitemid 32906679)
12. Jacoby GA, Mills DM, Chow N. Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48:3203-3206 (Pubitemid 38989206)
13. Woodford N, Dallow JWT, Hill RL, et al. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 2007; 29:456-459 (Pubitemid 46349596)
14. Lartigue MF, Poirel L, Poyart C, Réglier-Poupet H, Nordmann P. Ertapenem resistance of Escherichia coli. Emerg Infect Dis 2007; 13:315-317
15. Friedland IR, Issacs R, Mixson LA, Motyl M. Woods GL. Use of surrogate antimicrobial agents to predict susceptibility to ertapenem. Diagn Microbiol Infect Dis 2002; 43:61-64